Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA...
Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research
Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent and selective inhibitor of poly(ADP-ribose) polymerase-1 and -2 (PARP-1/2), with IC50 values of 5 nM and 1 nM, respectively, in biochemical assays (APExBIO). This compound induces synthetic lethality in BRCA1/2-deficient cancer cells by disrupting DNA single-strand break repair and is validated in both cell-based and in vivo models for enhanced radiosensitization and tumor cytotoxicity (McCrorie et al., 2020). Olaparib is widely used for DNA damage response assays, tumor radiosensitization studies, and as a tool for targeted therapy research (parathyroid-hormone1-34.com). APExBIO provides the compound in research-grade purity (SKU A4154), with validated protocols for both in vitro and in vivo use. Recent studies have also demonstrated the feasibility of nanoparticle-mediated, localized Olaparib delivery to overcome blood-brain barrier limitations in brain tumor models (McCrorie et al., 2020).
Biological Rationale
DNA repair is a critical cellular process that maintains genomic integrity. PARP-1 and PARP-2 are enzymes essential for the repair of single-strand DNA breaks via the base excision repair pathway. Inhibition of PARP activity leads to accumulation of DNA damage, particularly in tumor cells with defects in homologous recombination, such as those harboring BRCA1 or BRCA2 mutations (McCrorie et al., 2020). This concept, known as synthetic lethality, underpins the rationale for Olaparib use in cancer research targeting homologous recombination deficiency (HRD). Selective pressure against DNA repair-deficient cells, while sparing normal cells, enables targeted therapeutic approaches with improved specificity. Olaparib is also explored for enhancing radiosensitivity in tumor contexts where DNA repair pathways are compromised.
Mechanism of Action of Olaparib (AZD2281, Ku-0059436)
Olaparib binds to the catalytic domain of PARP-1 and PARP-2, inhibiting their enzymatic activity with high selectivity (IC50 = 5 nM for PARP-1; IC50 = 1 nM for PARP-2) (APExBIO). This inhibition impedes the repair of single-strand DNA breaks, resulting in the accumulation of DNA lesions. When replication forks encounter these lesions, they collapse, leading to double-strand breaks. In cells deficient in homologous recombination repair—such as those with BRCA1 or BRCA2 mutations—these double-strand breaks are not efficiently repaired, resulting in selective cell death (synthetic lethality) (cy3-maleimide.com). Olaparib also enhances caspase signaling and apoptosis in affected cells. Additionally, in experimental tumor models, Olaparib increases radiosensitivity, further amplifying DNA damage and cytotoxic effects (McCrorie et al., 2020).
Evidence & Benchmarks
- Olaparib inhibits PARP-1 and PARP-2 with IC50 values of 5 nM and 1 nM, respectively, in biochemical assays (APExBIO).
- In BRCA1/2-deficient tumor cells, Olaparib induces synthetic lethality by blocking DNA repair, leading to increased cell death in vitro and in vivo (McCrorie et al., 2020).
- Olaparib enhances radiosensitivity in non-small cell lung carcinoma (NSCLC) xenograft models, increasing DNA damage and improving tumor perfusion under controlled dosing conditions (parathyroid-hormone1-34.com).
- In localized delivery studies, Olaparib-loaded nanoparticles in a bioadhesive hydrogel enable targeted post-surgical administration to brain tumor sites, overcoming blood-brain barrier constraints (McCrorie et al., 2020).
- ATM kinase deficiency in cells increases sensitivity to Olaparib, reflecting the interplay between DNA damage response pathways (histone-h2a-107-122-ac-oh.com).
Applications, Limits & Misconceptions
Olaparib (AZD2281, Ku-0059436) is widely employed in cancer research for:
- DNA damage response assays to investigate PARP-mediated repair mechanisms.
- Tumor radiosensitization studies, particularly in NSCLC and glioblastoma models.
- Targeted therapy exploration in BRCA-associated cancers (breast, ovarian, prostate, pancreatic).
- Preclinical evaluation of synthetic lethality strategies in homologous recombination-deficient (HRD) cells.
This article updates and extends the mechanistic focus of "Olaparib (AZD2281): Unraveling PARP Inhibition in BRCA-Deficient Cancer Research" by detailing recent nanoparticle delivery approaches and quantitative benchmarks for radiosensitization. For practical workflow integration, see "Enhancing DNA Damage Response Assays with Olaparib (AZD2281, Ku-0059436)", which this article complements by providing updated in vivo delivery protocols and solubility data.
Common Pitfalls or Misconceptions
- Olaparib is not effective in tumors with functional homologous recombination repair (HRR). Only HRD contexts (e.g., BRCA mutations) show pronounced sensitivity (McCrorie et al., 2020).
- Systemic delivery is limited by the blood-brain barrier (BBB). Localized delivery methods are required for central nervous system tumors (McCrorie et al., 2020).
- Long-term storage of Olaparib in solution form is not recommended. Stock solutions should be stored below -20°C and used promptly (APExBIO).
- Olaparib is insoluble in ethanol and water. DMSO (≥21.72 mg/mL) is the recommended solvent for experimental use.
- Not all ATM-deficient tumors respond identically. Sensitivity modulation depends on the broader DNA damage response network.
Workflow Integration & Parameters
For in vitro studies, Olaparib is typically applied at 10 μM for 1 hour in cell culture experiments investigating DNA damage response or cell viability (parathyroid-hormone1-34.com). In vivo, intraperitoneal dosing of 50 mg/kg/day for 14 days in mouse models has been validated for tumor radiosensitization and cytotoxicity endpoints (McCrorie et al., 2020). The compound is soluble in DMSO at concentrations ≥21.72 mg/mL, and insoluble in ethanol and water. For optimal stability, prepare fresh aliquots and store below -20°C. APExBIO supplies Olaparib (A4154) with batch-specific purity and documentation (product page).
For further mechanistic and practical insights, see "Olaparib (AZD2281): Innovations in Localized PARP Inhibition", which this article extends by specifying validated dosing regimens and summarizing nanoparticle-mediated delivery evidence.
Conclusion & Outlook
Olaparib (AZD2281, Ku-0059436) is a validated, selective PARP-1/2 inhibitor with established utility in BRCA-deficient cancer research and DNA damage response assays. Its synthetic lethality mechanism enables targeted cytotoxicity in homologous recombination-deficient cells, and its radiosensitizing properties are confirmed in preclinical models. Nanoparticle-based, localized delivery strategies represent a promising direction for overcoming systemic delivery limitations, particularly for brain tumors. APExBIO’s Olaparib (A4154) remains a cornerstone reagent for researchers investigating PARP inhibition, synthetic lethality, and advanced cancer therapeutics.